Abbott Laboratories $ABT Shares Sold by Hendley & Co. Inc.

Hendley & Co. Inc. reduced its position in Abbott Laboratories (NYSE:ABT) by 6.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 99,374 shares of the healthcare product maker’s stock after selling 6,684 shares during the quarter. Abbott Laboratories comprises approximately 4.4% of Hendley & Co. Inc.’s investment portfolio, making the stock its 8th largest position. Hendley & Co. Inc.’s holdings in Abbott Laboratories were worth $12,451,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. Capital International Investors grew its holdings in Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after buying an additional 1,478,076 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after buying an additional 821,325 shares in the last quarter. Invesco Ltd. grew its holdings in Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Abbott Laboratories by 3.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after buying an additional 499,351 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

NYSE ABT opened at $84.49 on Friday. The stock has a market cap of $147.16 billion, a PE ratio of 23.67, a P/E/G ratio of 1.41 and a beta of 0.65. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The stock has a fifty day simple moving average of $99.02 and a 200-day simple moving average of $113.35.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 3.0%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Evercore dropped their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Wells Fargo & Company dropped their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. BTIG Research restated a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a report on Monday, April 27th. Weiss Ratings cut Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. Finally, Raymond James Financial dropped their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.43.

Insider Activity

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 in the last quarter. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.